Seek Returns

MRNA vs. VTRS: Moderna vs. Viatris Stock Comparison

How do Moderna (MRNA) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Moderna (MRNA) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MRNA is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for Moderna (MRNA) and Viatris (VTRS)
Profile ItemMRNAVTRS
NameModerna Inc.Viatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization101.48 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateDecember 7, 2018March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

MRNA
VTRS
GSPC
Loading price history…
Moderna (MRNA) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Moderna (MRNA) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Moderna (MRNA) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
Total Return (1Y)1,031.66%108.98%
Total Return (3Y, Annualized)58.68%36.75%
Total Return (5Y, Annualized)3.23%11.59%

Risk Profile

Drawdown History

MRNA
VTRS
GSPC
Loading price history…
Moderna (MRNA) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Moderna (MRNA) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
Volatility (1Y, Annualized)194.88%32.53%
Beta (5Y)1.080.86
Max Drawdown (5Y)-93.93%-45.69%
Avg. Volume (3M)21.61M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
MRNA and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
Sharpe Ratio (1Y)5.273.22
Sortino Ratio (1Y)20.445.63

Profitability

ROE (TTM)

Both Moderna (MRNA) at -39.00% and Viatris (VTRS) at -4.21% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max
109.18%
Q3
6.23%
Median
-26.66%
MRNA
-39.00%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Moderna (MRNA) at -141.43% and Viatris (VTRS) at -4.13% report negative net margin values, usually indicating net losses over the period.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
MRNA
-141.43%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Viatris (VTRS) reports 13.85%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
MRNA
-557.93%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
ROE (TTM)-39.00%-4.21%
ROA (TTM)-13.26%2.91%
Net Margin (TTM)-141.43%-4.13%
Operating Margin (TTM)-557.93%13.85%
Gross Margin (TTM)-66.02%41.13%

Growth

Revenue Growth

Both Moderna (MRNA) at -39.92% and Viatris (VTRS) at -2.98% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Moderna (MRNA) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
Revenue Growth (YoY)-39.92%-2.98%
Revenue Growth (3Y CAGR)-53.30%-4.20%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Moderna (MRNA) at 2.30 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MRNA
2.30
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Moderna (MRNA) at 0.19 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max
1.42
Q3
0.65
MRNA
0.19
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
Current Ratio (MRQ)2.301.55
Debt / Equity (MRQ)0.190.99
Net Debt / EBITDA--2.64

Dividends

Dividend Yield (TTM)

Moderna (MRNA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Moderna (MRNA) pays no dividend (payout 0.00%).

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

Neither Moderna (MRNA) nor Viatris (VTRS) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
MRNA
--

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 looks cheap on sales in the lower P/S ratio quartile, while Moderna (MRNA) at 45.55 looks rich in the upper quartile — a clear gap in price per dollar of revenue.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max
58.18
MRNA
45.55
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while Moderna (MRNA) at 11.58 carries a premium in the upper quartile — a clear price-to-book gap.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max
13.53
MRNA
11.58
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Moderna (MRNA) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Moderna (MRNA) and Viatris (VTRS)
MetricMRNAVTRS
P/E Ratio (TTM)----
P/S Ratio (TTM)45.551.55
P/B Ratio (MRQ)11.581.67
Free Cash Flow Yield (TTM)0.29%13.84%